- Home
- SKYE vs ASPC Comparison
SKYE vs ASPC Comparison
Compare SKYE & ASPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- ASPC
- Stock Information
- Founded
- SKYE 2012
- ASPC 2024
- Country
- SKYE United States
- ASPC Hong Kong
- Employees
- SKYE N/A
- ASPC N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- ASPC
- Sector
- SKYE Health Care
- ASPC
- Exchange
- SKYE Nasdaq
- ASPC Nasdaq
- Market Cap
- SKYE 80.7M
- ASPC 82.3M
- IPO Year
- SKYE N/A
- ASPC 2024
- Fundamental
- Price
- SKYE $1.98
- ASPC $10.16
- Analyst Decision
- SKYE Buy
- ASPC
- Analyst Count
- SKYE 6
- ASPC 0
- Target Price
- SKYE $16.60
- ASPC N/A
- AVG Volume (30 Days)
- SKYE 223.6K
- ASPC 11.0K
- Earning Date
- SKYE 05-08-2025
- ASPC 01-01-0001
- Dividend Yield
- SKYE N/A
- ASPC N/A
- EPS Growth
- SKYE N/A
- ASPC N/A
- EPS
- SKYE N/A
- ASPC 0.05
- Revenue
- SKYE N/A
- ASPC N/A
- Revenue This Year
- SKYE N/A
- ASPC N/A
- Revenue Next Year
- SKYE N/A
- ASPC N/A
- P/E Ratio
- SKYE N/A
- ASPC $218.81
- Revenue Growth
- SKYE N/A
- ASPC N/A
- 52 Week Low
- SKYE $1.14
- ASPC $9.95
- 52 Week High
- SKYE $12.11
- ASPC $10.51
- Technical
- Relative Strength Index (RSI)
- SKYE 50.21
- ASPC N/A
- Support Level
- SKYE $1.88
- ASPC N/A
- Resistance Level
- SKYE $2.28
- ASPC N/A
- Average True Range (ATR)
- SKYE 0.23
- ASPC 0.00
- MACD
- SKYE 0.00
- ASPC 0.00
- Stochastic Oscillator
- SKYE 40.00
- ASPC 0.00
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About ASPC A SPAC III Acquisition Corp. Class A Ordinary Shares
A SPAC III Acquisition Corp is a blank check company.